Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004

Trial Profile

Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 23 Jul 2018

At a glance

  • Drugs Denosumab (Primary)
  • Indications Giant cell tumours
  • Focus Adverse reactions
  • Sponsors Amgen
  • Most Recent Events

    • 16 Jul 2018 Planned End Date changed from 22 Jul 2023 to 19 Jul 2023.
    • 16 Jul 2018 Planned primary completion date changed from 22 Jul 2023 to 19 Jul 2023.
    • 16 Jul 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top